PetMedix Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • PetMedix's estimated annual revenue is currently $3.9M per year.(i)
  • PetMedix's estimated revenue per employee is $77,500

Employee Data

  • PetMedix has 50 Employees.(i)
  • PetMedix grew their employee count by 0% last year.

PetMedix's People

NameTitleEmail/Phone
1
Founder & CEOReveal Email/Phone
2
Founder & CEOReveal Email/Phone
3
Head NGS PipelineReveal Email/Phone
4
Head External ProgramsReveal Email/Phone
5
Head Business DevelopmentReveal Email/Phone
6
Head Antibody DiscoveryReveal Email/Phone
7
Head Research and InnovationReveal Email/Phone
8
Chief Product Development OfficerReveal Email/Phone
9
Director OperationsReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is PetMedix?

PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. We are using the highest quality science to make the therapies our pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, we are applying the cutting edge of science to bring breakthroughs for the animals we love and care for. PetMedix is taking the experience of its founding team, and decades of human clinical research, to build platforms that generate fully species-specific, naturally-generated therapeutic antibodies. These platforms have been designed to generate a repertoire of antibodies as diverse as the companion animal immune systems on which they are based. These platforms can then be used to develop a broad pipeline of our own veterinary medicines to target under-served clinical areas that represent excellent market opportunities. We are actively recruiting so please get in touch if you wish to join our hard-working and talented team.

keywords:N/A

N/A

Total Funding

50

Number of Employees

$3.9M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

PetMedix News

2021-09-08 - PetMedix – closes $37m Series B round

Parkwalk are pleased to announce an investment in PetMedix a Cambridge University spin out, leading the way in antibody innovation in animal health. Parkwalk co-led the $37m Series B funding round with Digitalis Ventures. PetMedix™ announces today the completion of an oversubscribed $37M (£27M) ...

2021-09-08 - PetMedix Raises $37M in Series B Funding

PetMedix, a Cambridge UK-based animal health company, raised $37M in Series B funding. The round was led by Tencent and Kyoritsu Holdings with participation from Digitalis Ventures, Parkwalk Advisors and Cambridge Innovation Capital. The company intends to use the funds to advance its innovati ...

2020-02-21 - PetMedix wins Best Start-up 2019 in the Animal Pharm Awards

PetMedix wins Best Start-up 2019 in the Animal Pharm Awards 21-02-2020 PetMedix has been voted best start-up in the global Animal Pharm Awards. The UK-based start-up is developing a new tier of monoclonal antibody therapy for the animal health market. Situated in the heart of the Cambridge bio ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.8M50N/AN/A
#2
$5.5M50-6%$2.3M
#3
$7.8M5025%N/A
#4
$5.6M5014%N/A
#5
$7.8M50-4%N/A